A Descriptive, Comparative, Randomized, Crossover Study of Flurpiridaz (18F) Injection for Positron Emission Tomography (PET) Imaging for Assessment of Myocardial Perfusion Imaging Quality Using High Performance Liquid Chromatography (HPLC) and Solid Phase Extraction (SPE) Manufacturing Processes

This was a Phase 2 prospective, randomized, crossover study of Flurpiridaz (18F) Injection for PET-MPI in participants referred for evaluation of known coronary artery disease (CAD) or for suspected CAD with intermediate to high pre-test probability (PTP). The objective is to assess the difference and variability between 2 sets of rest images synthesized by the same or 2 different manufacturing processes. Twenty-eight evaluable [participants were enrolled in this study and underwent 2 Flurpiridaz (18F) Injection PET-MPI at rest. Each participant attended a Screening Visit at least 2 days and up to 14 days prior to the first Flurpiridaz (18F) Injection PET-MPI. The participants were randomized 1:1:1:1 to 4 possible sequences of receiving 2 doses of Flurpiridaz (18F) Injection: 2 groups of 7 participants received 2 Flurpiridaz (18F) Injection doses synthesized by the same manufacturing processes (either HPLC or SPE) and 2 groups of 7 subjects will receive 2 Flurpiridaz (18F) Injection doses synthesized by different manufacturing processes (1 dose by HPLC followed by 1 dose by SPE or 1 dose by SPE followed by 1 dose by HPLC). All participants were followed up by telephone for adverse events (AEs) and serious AEs (SAEs) at 24 (+8) hours following each Flurpiridaz (18F) Injection administration.

开始日期2022-01-27

申办/合作机构

GE Healthcare Holdings, Inc.

NCT03354273 / Completed临床3期

A Phase 3, Open-Label, Multicentre Study of Flurpiridaz (18F) Injection for Positron Emission Tomography (PET) Imaging for Assessment of Myocardial Perfusion in Patients Referred for Invasive Coronary Angiography Because of Suspected Coronary Artery Disease

This is a Phase 3, prospective, open-label, international, multicentre study of Flurpiridaz (18F) Injection for PET MPI in patients referred for ICA because of suspected CAD.

开始日期2018-06-05

申办/合作机构

GE Healthcare Holdings, Inc.

[+1]

NCT01085162 / WithdrawnN/A

An Open-Label Prospective, Non-Randomized, International, Multi-center, Long-term Follow-up Study to Evaluate the Predictive Value of BMS747158 Positron Emission Tomography (PET) Myocardial Perfusion Imaging (MPI) in Patients Suspected of Coronary Artery Disease (CAD)

This long-term study will follow patients with known or suspected of having coronary artery disease (CAD) and have participated in present and future BMS747158 clinical studies. The purpose of this study is to evaluate the long-term predictive value associated with BMS747158 Positron Emission Tomography (PET) Myocardial Perfusion Imaging (MPI).

开始日期2013-03-31

申办/合作机构

Lantheus Medical Imaging, Inc.

100 项与 Flurpiridaz F-18 相关的临床结果

登录后查看更多信息

100 项与 Flurpiridaz F-18 相关的转化医学

登录后查看更多信息

100 项与 Flurpiridaz F-18 相关的专利（医药）

登录后查看更多信息

项与 Flurpiridaz F-18 相关的文献（医药）

2023-12-01·European Journal of Nuclear Medicine and Molecular Imaging

Integrated myocardial flow reserve (iMFR) assessment: optimized PET blood flow quantification for diagnosis of coronary artery disease

Article

作者: Buckley, Christopher J ; Hagio, Tomoe ; Ficaro, Edward P ; Al-Mallah, Mouaz H ; Arida-Moody, Liliana ; Weinberg, Richard L ; Renaud, Jennifer M ; Moody, Jonathan B ; Murthy, Venkatesh L ; Nallamothu, Brahmajee K ; Poitrasson-Rivière, Alexis

PURPOSEDistinguishing obstructive epicardial coronary artery disease (CAD) from microvascular dysfunction and diffuse atherosclerosis would be of immense benefit clinically. However, quantitative measures of absolute myocardial blood flow (MBF) integrate the effects of focal epicardial stenosis, diffuse atherosclerosis, and microvascular dysfunction. In this study, MFR and relative perfusion quantification were combined to create integrated MFR (iMFR) which was evaluated using data from a large clinical registry and an international multi-center trial and validated against invasive coronary angiography (ICA).METHODSThis study included 1,044 clinical patients referred for ⁸²Rb rest/stress positron emission tomography myocardial perfusion imaging and ICA, along with 231 patients from the Flurpiridaz 301 trial (clinicaltrials.gov NCT01347710). MFR and relative perfusion quantification were combined to create an iMFR map. The incremental value of iMFR was evaluated for diagnosis of obstructive stenosis, adjusted for patient demographics and pre-test probability of CAD. Models for high-risk anatomy (left main or three-vessel disease) were also constructed.RESULTSiMFR parameters of focally impaired perfusion resulted in best fitting diagnostic models. Receiver-operating characteristic analysis showed a slight improvement compared to standard quantitative perfusion approaches (AUC 0.824 vs. 0.809). Focally impaired perfusion was also associated with high-risk CAD anatomy (OR 1.40 for extent, and OR 2.40 for decreasing mean MFR). Diffusely impaired perfusion was associated with lower likelihood of obstructive CAD, and, in the absence of transient ischemic dilation (TID), with lower likelihood of high-risk CAD anatomy.CONCLUSIONSFocally impaired perfusion extent derived from iMFR assessment is a powerful incremental predictor of obstructive CAD while diffusely impaired perfusion extent can help rule out obstructive and high-risk CAD in the absence of TID.

2023-10-01·Journal of the American College of Cardiology

Flurpiridaz F-18 PET Myocardial Perfusion Imaging in Patients With Suspected Coronary Artery Disease

Article

作者: Bateman, Timothy M ; Knuuti, Juhani M ; Maddahi, Jamshid ; Heller, Gary V ; Agostini, Denis ; Garcia, Ernest V ; Udelson, James E ; Feldman, James ; Martinez-Clark, Pedro ; Shepple, Benjamin ; Bax, Jeroen J ; Beanlands, Rob S B ; Tamaki, Nagara ; Berman, Daniel S ; Pelletier-Galarneau, Matthieu ; Dorbala, Sharmila ; Tranquart, Francois

BACKGROUNDFlurpiridaz F-18 (flurpiridaz) is a novel positron emission tomography (PET) myocardial perfusion imaging tracer.OBJECTIVESThe purpose of this study was to further assess the diagnostic efficacy and safety of flurpiridaz for the detection and evaluation of coronary artery disease (CAD) defined as ≥50% stenosis by quantitative invasive coronary angiography (ICA).METHODSIn this second phase 3 prospective multicenter clinical study, 730 patients with suspected CAD from 48 clinical sites in the United States, Canada, and Europe were enrolled. Patients underwent 1-day rest/stress flurpiridaz PET and 1- or 2-day rest-stress Tc-99m-labeled single photon emission computed tomography (SPECT) before ICA. PET and SPECT images were read by 3 experts blinded to clinical and ICA data.RESULTSA total of 578 patients (age 63.7 ± 9.5 years) were evaluable; 32.5% were women, 52.3% had body mass index ≥30 kg/m², and 33.6% had diabetes. Flurpiridaz PET met the efficacy endpoints of the study; its sensitivity and specificity were significantly higher than the prespecified threshold value by 2 of the 3 readers. The sensitivity of flurpiridaz PET was higher than SPECT (80.3% vs 68.7%; P = 0.0003) and its specificity was noninferior to SPECT (63.8% vs 61.7%; P = 0.0004). PET area under the receiver-operating characteristic curves were higher than SPECT in the overall population (0.80 vs 0.68; P < 0.001), women, and obese patients (P < 0.001 for both). Flurpiridaz PET was superior to SPECT (P < 0.001) for perfusion defect size/severity evaluation, image quality, diagnostic certainty, and radiation exposure. Flurpiridaz PET was safe and well tolerated.CONCLUSIONSThis second flurpiridaz PET myocardial perfusion imaging trial shows that flurpiridaz has utility as a new tracer for CAD detection, specifically in women and obese patients. (An International Study to Evaluate Diagnostic Efficacy of Flurpiridaz [18F] Injection PET MPI in the Detection of Coronary Artery Disease [CAD]; NCT03354273).

2023-03-01·European Journal of Nuclear Medicine and Molecular Imaging

Multi-center, multi-vendor validation of deep learning-based attenuation correction in SPECT MPI: data from the international flurpiridaz-301 trial

Article

作者: Buckley, Christopher ; Poitrasson-Rivière, Alexis ; Murthy, Venkatesh L ; Moody, Jonathan B ; Renaud, Jennifer M ; Ficaro, Edward P ; Hagio, Tomoe ; Pierce, Lora

PURPOSEAlthough SPECT myocardial perfusion imaging (MPI) is susceptible to artifacts from soft tissue attenuation, most scans are performed without attenuation correction. Deep learning-based attenuation corrected (DLAC) polar maps improved diagnostic accuracy for detection of coronary artery disease (CAD) beyond non-attenuation-corrected (NAC) polar maps in a large single center study. However, the generalizability of this approach to other institutions with different scanner models and protocols is uncertain. In this study, we evaluated the diagnostic performance of DLAC compared to NAC for detection of CAD as defined by invasive coronary angiography (ICA) in a large multi-center trial.METHODSDuring the phase 3 flurpiridaz multi-center diagnostic clinical trial, conducted over 74 international sites, patients with known or suspected CAD who were referred for a clinically indicated ICA were enrolled. Using receiver operating characteristic (ROC) analysis, we evaluated the detectability of obstructive CAD, defined by quantitative coronary angiography by a core laboratory, using total perfusion deficit (TPD) as an integrated measure of defect extent and severity on DLAC polar maps compared to NAC polar maps. This was also compared against the visual scoring of three expert core lab readers.RESULTSOut of 755 patients, 722 (69% male) had evaluable SPECT and ICA for this study. ROC analysis demonstrated significant improvement in detecting per-patient obstructive CAD with DLAC over NAC with area under the curve (AUC) of 0.752 (95% CI: 0.711-0.792) for DLAC compared to 0.717 (0.675-0.759) for NAC (p value = 0.016). Compared to the consensus of expert readers AUC = 0.743 (0.701-0.784), DLAC was comparable (p value = 0.913), whereas NAC underperformed (p value = 0.051).CONCLUSIONDL-based attenuation correction improves diagnostic performance of SPECT MPI for detecting CAD in data from a large multi-center clinical trial regardless of SPECT camera model or protocol.TRIAL REGISTRATIONA Phase 3 Multi-center Study to Assess PET Imaging of Flurpiridaz F 18 Injection in Patients With CAD, ClinicalTrials.gov Identifier: NCT01347710, registered on 4 May 2011. https://clinicaltrials.gov/ct2/show/study/NCT01347710.

项与 Flurpiridaz F-18 相关的新闻（医药）

2024-02-07

·FierceBiotech

GE HealthCare plots theranostics growth as it beats earnings estimates in first solo year

“In the next three years, we plan to significantly increase our current theranostics franchise through a combination of organic and inorganic expansions,” GE HealthCare President and CEO Peter Arduini said on the company's fourth-quarter earnings call. In its first full 12 months as an independent, public company, GE HealthCare posted an 8% boost in organic annual revenue—but the company said it doesn’t expect that trajectory to continue into its sophomore year. The imaging giant has set its 2024 expectations at 4% organic sales growth. On a call with investors for the company’s fourth-quarter earnings report this week, Chief Financial Officer Jay Saccaro attributed last year’s gains to recovering supply chains and pricing advantages. “And a lot of that came down to execution, in terms of translating backlog into sales—which was a testament to the work by many of our teams. So, as we look to 2024, we think roughly 4% is a solid number,” said Saccaro, who also described 2023’s 8% figure as the high end of the company’s previous full-year predictions and “in excess of our expectations for the fourth quarter.” In terms of total revenue, GE HealthCare brought in $19.6 billion during 2023—including $10.6 billion from its CT and MRI imaging systems, $3.5 billion from ultrasound devices, $3.1 billion in patient care and monitoring solutions and $2.3 billion from pharmaceutical diagnostics. That last portfolio, with its nuclear medicine and cancer-targeting imaging tracers, grew 18% year-over-year and 23% in the fourth quarter, driven by global expansions in diagnostic procedures and their need for imaging agents. “As novel therapies become more widely available, our tracers will play an increasingly important role—putting us at the center of this transformation of care that will help enable better patient outcomes across many pathways as functional imaging expands,” President and CEO Peter Arduini said on the investor call. “We see growth opportunities with our existing products—like Vizamyl for patients with suspected Alzheimer’s disease, as new therapies ramp up—and Cerianna for metastatic breast cancer, which are both used in conjunction with PET systems for diagnosis,” Arduini added. “And Flurpiridaz, a pipeline product for diagnosing and assessing coronary artery disease, is expected to significantly advance PET/CT imaging.” These injectable imaging tools are also expected to help set the stage as patient care turns more toward theranostic procedures, blurring the lines between discrete tests and treatments. “To give you some perspective, currently the overall theranostics market—which includes equipment, tracers and therapies—is about $9 billion and expected to grow to $40 billion by 2032,” Arduini said. “Today, theranostics are primarily used in thyroid, neuroendocrine and prostate tumors. However, a growing pipeline of drugs across the industry that includes breast, ovarian, pancreatic and lung cancers shows even more promise.” “In the next three years, we plan to significantly increase our current theranostics franchise through a combination of organic and inorganic expansions,” he said, highlighting GE HealthCare’s recently proposed acquisition of the AI developer MIM Software and its plans to integrate the latter’s imaging analysis programs for radiation oncology, molecular radiotherapy, urology and theranostics in particular. GE HealthCare’s first year also saw the company pay down $1 billion in debt while putting more than $1 billion into its R&D spend and launching more than 40 new products. “As a result of our investments, we estimate that we have gained global market share in equipment in 2023. And, once again, we topped the FDA’s list of AI-enabled device authorizations with 58, more than any other medtech company,” Arduini said, referring to the agency’s accounting. “Our backlog remains robust, led by an improved capital equipment landscape.” For the fourth quarter of 2023, the company posted $5.2 billion in sales for a 5% gain over the same period the year before. Net income, however, dropped to $403 million from $554 million, while the accounting for the full year fell to $1.6 billion, compared to 2022’s $1.9 billion. All told, the price of GE HealthCare’s stock on the Nasdaq jumped more than 12% following its earnings release, to more than $81 per share. The company completed its split from the General Electric mothership in January 2023.

并购

2022-09-14

·NS Medical Devices

GE Healthcare and Lantheus Phase III Clinical Trial Finds flurpiridaz PET Radiotracer Could Improve Detection of Coronary Artery Disease

Phase III clinical trial of flurpiridaz PET diagnostic radiopharmaceutical meets co-primary endpoints for detecting Coronary Artery Disease (CAD) This radiotracer is part of GE Healthcare’s pipeline of Molecular Imaging diagnostics aiming to increase diagnostic accuracy and improve patient outcomes across key care areas. (Credit: Robina Weermeijer on Unsplash) GE Healthcare and Lantheus Holdings have announced that the recent Phase III clinical trial of their investigational radiotracer, flurpiridaz, has met its co-primary endpoints of exceeding a 60 percent threshold for both sensitivity and specificity for detecting Coronary Artery Disease (CAD). The findings, shared at the American Society of Nuclear Cardiology (ASNC) Congress, in Florida, U.S., also demonstrate flurpiridaz Positron Emission Tomography (PET) has higher diagnostic efficacy and image quality in patients with suspected CAD, compared with Single Photon Emission Computed Tomography (SPECT) Myocardial Perfusion Imaging (MPI), the predominant procedure used in nuclear cardiology today. SPECT MPI represents approximately 6 million procedures per year in the U.Si. The Phase III Open-Label Study, which involved over 600 patients across sites in the U.S., Europe and Canada assessed the diagnostic efficacy of flurpiridaz in detecting CAD, the most common form of heart diseaseii and the leading cause of death globallyiii, with invasive coronary angiography as a standard of truth. More than 120 million people are affected by CAD globally each yeariv and in the U.S. alone, approximately 20 million adults have CAD, with nearly 383,000 deaths recorded in 2020v. If approved, this investigational agent would offer the advantages of 18F, with broad available distribution and a half-life of almost two hours, removing the need for it to be manufactured in the immediate vicinity of the imaging department. This longer half-life could also make Flurpiridaz (18F) Injection suitable for exercise stress testing, which is not feasible with existing cardiac PET radiotracers. Dr. Tim Bateman, MD, FACC, co-director of the Cardiovascular Radiologic Imaging Program at Saint Luke’s Hospital, Missouri, US, shared: “These results are truly promising for the nuclear cardiology community and CAD patients. From ASNC’s inception, its leaders have laid out the specifications for an ideal myocardial perfusion tracer. In my view [18F]flurpiridaz could meet this goal, expanding how PET MPI can be used to image CAD patients moving forward.” Dr. Francois Tranquart, MD, PhD, Global Head of Clinical Development for GE Healthcare Pharmaceutical Diagnostics, Research and Development, said: “The positive Phase III trial results are a key step towards future approval of Flurpiridaz Injection as a potential new cardiac PET agent which could improve the detection of coronary artery disease. This is another example of GE Healthcare investing in our portfolio of Molecular Imaging products to help improve diagnostic accuracy and patient outcomes.” GE Healthcare has led the funding and development of flurpiridaz, and, if the imaging agent is approved, will have global commercialization rights. Lantheus has collaborated on the development and will also collaborate on potential commercialization through a joint steering committee. Lantheus is entitled to royalties based on commercial sales. GE Healthcare’s Pharmaceutical Diagnostics unit is a global leader in imaging agents used to support around 100 million procedures per year globally, equivalent to three patients every second. Its Molecular Imaging portfolio combines an innovative pipeline with established proprietary products across cardiology, neurology and oncology. Source: Company Press Release

合作

2022-09-13

·Mass Device

GE Healthcare, Lantheus radiotracer trial meets endpoints

The Phase III clinical trial for the Flurpiridaz radiotracer met its co-primary endpoints. It exceeded a 60% threshold for both sensitivity and specificity in detecting coronary artery disease (CAD). GE and Lantheus shared the results at the American Society of Nuclear Cardiology (ASNC) Congress, in Florida. According to a news release, the data also demonstrate higher diagnostic efficacy and image quality for the radiotracer. These data compared Flurpiridaz to single photon emission computed tomography (SPECT) myocardial perfusion imaging (MPI). The trial included over 600 patients across sites in the U.S., Europe and Canada. It assessed the diagnostic efficacy of Flurpiridaz in detecting CAD with invasive coronary angiography as a standard of truth. The companies said that, if approved, the investigational agent would offer broad available distribution and a half-life of almost two hours. That half-life removes the need for it to be manufactured in the immediate vicinity of the imaging department. It could also make it suitable for exercise stress testing, which is not currently feasible with existing cardiac PET radiotracers. “These results are truly promising for the nuclear cardiology community and CAD patients,” said Dr. Tim Bateman, co-director of the cardiovascular radiologic imaging program at Saint Luke’s Hospital, Missouri. “From ASNC’s inception, its leaders have laid out the specifications for an ideal myocardial perfusion tracer. In my view Flurpiridaz could meet this goal, expanding how PET MPI can be used to image CAD patients moving forward.” GE Healthcare leads the funding and development of Flurpiridaz. If it is approved, the company will hold global commercialization rights. Lantheus collaborated on the development and will collaborate on potential commercialization through a joint steering committee. It is entitled to royalties based on commercial sales. “The positive Phase III trial results are a key step towards future approval of Flurpiridaz injection as a potential new cardiac PET agent which could improve the detection of coronary artery disease,” said Dr. Francois Tranquart, global head of clinical development for GE Healthcare Pharmaceutical Diagnostics. This is another example of GE Healthcare investing in our portfolio of molecular imaging products to help improve diagnostic accuracy and patient outcomes.”

合作

100 项与 Flurpiridaz F-18 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
冠心病	申请上市	美国	Lantheus Medical Imaging, Inc.	2011-06-01
心血管疾病	临床3期	美国	GE Healthcare Ltd. (United Kingdom)	2022-01-30
心血管疾病	临床3期	美国	Progenics Pharmaceuticals, Inc.	2022-01-30
冠心病	临床3期	芬兰	Lantheus Medical Imaging, Inc.	2011-06-01
冠心病	临床2期	加拿大	Lantheus Medical Imaging, Inc.	2011-06-01
冠心病	临床1期	加拿大	Lantheus Medical Imaging, Inc.	2011-06-01
冠心病	临床1期	芬兰	Lantheus Medical Imaging, Inc.	2011-06-01
冠心病	临床前	美国	Lantheus Medical Imaging, Inc.	2011-06-01
肿瘤	临床前	德国	Bayer AG	2009-04-01
缺血	临床前	美国	Lantheus Medical Imaging, Inc.	2009-01-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT01347710 (CTgov)	临床3期	冠心病	795	Flurpiridaz F18 (Flurpiridaz F18 PET MPI)	窪鹹廠憲襯淵夢鏇淵範(襯襯鑰鏇憲廠齋顧蓋鬱) = 鏇積顧淵鏇衊製襯壓淵衊簾窪網獵膚餘簾鬱夢 (襯蓋積繭齋夢製顧淵簾, 淵願顧鏇壓餘蓋範淵鹽 ~ 鏇醖夢網鏇廠顧憲餘築) 更多	-	2016-04-05
				Flurpiridaz F (Flurpiridaz F 18)	糧膚廠製鏇繭壓製淵構(構簾淵顧壓膚積獵艱餘) = 範觸簾窪簾蓋遞繭鑰觸簾製艱衊顧醖廠廠獵餘 (鹽範襯夢網顧繭廠範簾, 鬱鹹醖製醖鏇窪構鑰衊 ~ 鬱糧齋壓夢範餘築醖簾) 更多
NCT03354273 (CTgov)	临床3期	冠心病	730	Flurpiridaz (18F) (Flurpiridaz (18F))	(憲襯觸夢積膚齋製簾壓) = 壓築選構鹹鑰構憲積糧製製夢獵選憲衊鹹網網 (壓構鏇膚顧觸窪鏇衊壓, 繭襯糧鹹廠簾餘鹽選糧 ~ 範襯網夢壓構鬱餘鏇壓) 更多	-	2023-07-12
				Flurpiridaz (18F) (Flurpiridaz (18F) PET MPI)	(鬱願願膚網憲遞鹹窪鏇) = 衊艱範網網鹹範鹽廠壓觸蓋襯顧醖遞衊鹹鹹築 (壓範齋積膚艱憲繭觸觸, 簾淵餘壓築獵衊鏇糧簾 ~ 繭餘簾網醖繭夢鹹鑰壓) 更多
ESC2023	临床3期	冠心病	730	Flurpiridaz PET	積淵淵選醖夢糧衊艱鑰(淵構願獵醖構選壓獵鏇) = 淵簾鹽艱餘鏇醖襯淵製鏇鑰觸繭餘獵築醖鏇獵 (艱襯衊構網糧範齋積衊 )	-	2023-08-27
				flurpiridaz F-18	積淵淵選醖夢糧衊艱鑰(淵構願獵醖構選壓獵鏇) = 積淵獵壓繭鏇鹽觸選鹽鏇鑰觸繭餘獵築醖鏇獵 (艱襯衊構網糧範齋積衊 )
NCT01347710 (Pubmed \| J Am Coll Cardiol) 人工标引	临床3期	冠心病	755	Fluorine-18 Flurpiridaz (PET)	餘鹹鹽遞選積衊鹽鑰鹽(夢遞鹽蓋憲壓築衊廠觸) = 製願範願衊糧繭繭選簾範築顧遞範淵鏇獵淵夢 (餘顧構顧鏇築製蓋鏇鏇, 0.4) 更多	积极	2020-07-28
				Fluorine-18 Flurpiridaz (SPECT)	餘鹹鹽遞選積衊鹽鑰鹽(夢遞鹽蓋憲壓築衊廠觸) = 繭範範廠醖製網鹽壓鹽範築顧遞範淵鏇獵淵夢 (餘顧構顧鏇築製蓋鏇鏇, 3.2 ) 更多
NCT00849108 (CTgov)	临床2期	缺血	176	BMS747158	壓鏇糧夢製膚齋範選製(顧夢鹹築鹽選遞鏇蓋網) = 範築蓋衊夢選積衊網鬱蓋簾製襯鬱製願壓糧壓 (夢廠鹹淵構醖壓製鹽壓, 獵壓鬱壓構憲壓願膚衊 ~ 膚鑰醖艱鹹餘壓繭糧獵) 更多	-	2015-01-19
NCT04594941 (CTgov)	临床2期	冠心病	38	Flurpiridaz (18F) (Flurpiridaz (18F): SPE)	網夢簾鹽製艱衊鏇廠艱(簾願廠艱遞構醖積繭繭): Least Sqaure (LS) Mean Difference = -0.149 (90.0% CI, -1.431 ~ 1.133); LS Mean Difference = -0.015 (90.0% CI, -1.899 ~ 1.868); LS Mean Difference = -0.753 (90.0% CI, -2.204 ~ 0.698); LS Mean Difference = -0.091 (90.0% CI, -1.735 ~ 1.554) 更多	-	2023-08-01
				Flurpiridaz (18F) (Flurpiridaz (18F): HPLC)